Vice President, Quality Assurance

Olema Oncology is  a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with  breast cancer  and beyond.   It’s  an exciting time to be part of Team Olema ,  with   our transfor mation into a fully   integrated oncology company well underway ,  t op-line data from our lead program expected  later  this  year ,   and our first potential commercial launch on the horizon. Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in the fall which, if successful, could lead to our first potential approval and commercial launch in 2027. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant has the potential to transform the metastatic breast cancer treatment paradigm and access a $15 billion global market opportunity. Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently reported encouraging Phase 1 monotherapy data from this program across multiple solid tumor types and are advancing patient enrollment in the ongoing combination arms in MBC. Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and a passionate team dedicated to helping the patients we serve feel better, longer. We possess a deep commitment to our shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution.  Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day. If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together –  for  our patients, for your career,  and  for  what’s  beyond . About the Role >>> Vice President, Quality   Assurance    The  Vice President, Quality Assurance  serves as the senior leader accountable for defining and driving Olema’s global quality strategy, systems, and governance across the full product lifecycle, including clinical development, manufacturing, pharmacovigilance, and commercial. This leader is the primary voice of Quality at the executive level and ensures a phase-appropriate, risk-based approach to quality that reflects the needs of oncology drug development, where patient safety, data integrity, and speed are critical.   Operating with appropriate independence, this role partners cross-functionally and leads an established Quality leadership team across GCP, GMP, and GPV - aligning priorities, strengthening execution, and ensuring inspection readiness as Olema advances toward late-stage development. This role is based out of our either our San Francisco, CA or Boston, MA office and will require some travel as needed.   As Vice President, Quality Assurance , your work will  primarily encompass: Quality Strategy & Leadership    Define and drive a pragmatic, phase-appropriate and unified Quality strategy aligned with Olema’s pipeline and corporate objectives    Serve as the senior Quality leader, establishing clear governance, decision-making frameworks, and escalation pathways    Lead and develop Quality leadership across GCP, GMP, and GPV, enabling strong execution and maintaining clear accountability    Foster a culture of quality, integrity, and patient focus across the organization    Act as escalation point for significant quality, compliance, and patient safety risks    Ensure ongoing inspection readiness across clinical, manufacturing, and safety domains  Quality Systems & Governance     Set expectations and direction for a scalable, integrated, and sustainable Quality Management framework spanning clinical through commercial stages    Ensure effectiveness and evolution of Quality systems through oversight of functional leaders across the QA function    Drive consistency in quality processes, risk management approaches, and data integrity standards across the organization    Establish clear quality metrics and reporting to enable risk visibility and informed decision-making  Clinical Quality (GCP)     Ensure Quality approaches appropriately support the execution of oncology clinical trials    Provide oversight of clinical quality and CRO management to ensure patient safety and data integrity    Partner with Clinical and Regulatory to support inspection-ready programs and submissions Manufacturing & Commercial Readiness (GMP)    Ensure Quality strategy supports manufacturing scale-up and readiness for late-stage development and commercialization    Oversee GMP Quality through established leadership, ensuring appropriate CMO/CDMO oversight and inspection preparedness    Provide Quality input into CMC, validation, and supply chain readiness activities Pharmacovigilance Quality (GPV)    Oversee the pharmacovigilance quality framework, ensuring compliance, data integrity, and effective safety surveillance    Ensure PV systems and vendors are appropriately governed and inspection-ready    Partner cross-functionally to support ongoing evaluation of benefit-risk Inspection, Audit & Risk Management